AXSM Annual CFO
-$145.08 M
-$28.57 M-24.52%
31 December 2023
Summary:
As of January 22, 2025, AXSM annual cash flow from operations is -$145.08 million, with the most recent change of -$28.57 million (-24.52%) on December 31, 2023. During the last 3 years, it has fallen by -$66.62 million (-84.92%). AXSM annual CFO is now -8794.61% below its all-time high of -$1.63 million, reached on December 31, 2013.AXSM Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AXSM Quarterly CFO
-$18.63 M
+$11.48 M+38.12%
30 September 2024
Summary:
As of January 22, 2025, AXSM quarterly cash flow from operations is -$18.63 million, with the most recent change of +$11.48 million (+38.12%) on September 30, 2024. Over the past year, it has increased by +$11.73 million (+38.64%). AXSM quarterly CFO is now -1507.65% below its all-time high of -$1.16 million, reached on March 31, 2015.AXSM Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AXSM TTM CFO
-$132.57 M
+$34.92 M+20.85%
30 September 2024
Summary:
As of January 22, 2025, AXSM TTM cash flow from operations is -$132.57 million, with the most recent change of +$34.92 million (+20.85%) on September 30, 2024. Over the past year, it has increased by +$12.51 million (+8.62%). AXSM TTM CFO is now -11339.30% below its all-time high of -$1.16 million, reached on March 31, 2015.AXSM TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AXSM Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.5% | +38.6% | +8.6% |
| 3 y3 years | -84.9% | +30.4% | -32.6% |
| 5 y5 years | -382.7% | -75.3% | -185.9% |
AXSM Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -34.0% | at low | -220.1% | +66.3% | -47.8% | +31.2% |
| 5 y | 5-year | -212.8% | at low | -220.1% | +66.3% | -185.9% | +31.2% |
| alltime | all time | -8794.6% | at low | -1507.7% | +66.3% | <-9999.0% | +31.2% |
Axsome Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$18.63 M(-38.1%) | -$132.57 M(-20.8%) |
| June 2024 | - | -$30.11 M(-43.7%) | -$167.49 M(-13.1%) |
| Mar 2024 | - | -$53.47 M(+76.1%) | -$192.73 M(+32.8%) |
| Dec 2023 | -$145.08 M(+24.5%) | -$30.36 M(-43.3%) | -$145.08 M(+2.0%) |
| Sept 2023 | - | -$53.55 M(-3.3%) | -$142.28 M(+27.6%) |
| June 2023 | - | -$55.35 M(+850.9%) | -$111.49 M(+24.3%) |
| Mar 2023 | - | -$5.82 M(-78.9%) | -$89.68 M(-23.0%) |
| Dec 2022 | -$116.51 M(+7.7%) | -$27.56 M(+21.1%) | -$116.51 M(-1.1%) |
| Sept 2022 | - | -$22.76 M(-32.1%) | -$117.79 M(-3.3%) |
| June 2022 | - | -$33.54 M(+2.7%) | -$121.81 M(+7.2%) |
| Mar 2022 | - | -$32.65 M(+13.2%) | -$113.66 M(+5.0%) |
| Dec 2021 | -$108.23 M(+37.9%) | -$28.84 M(+7.7%) | -$108.23 M(+8.3%) |
| Sept 2021 | - | -$26.78 M(+5.4%) | -$99.94 M(+12.4%) |
| June 2021 | - | -$25.39 M(-6.7%) | -$88.90 M(+7.9%) |
| Mar 2021 | - | -$27.22 M(+32.4%) | -$82.40 M(+5.0%) |
| Dec 2020 | -$78.46 M(+69.2%) | -$20.55 M(+30.6%) | -$78.46 M(+4.0%) |
| Sept 2020 | - | -$15.73 M(-16.7%) | -$75.47 M(+7.3%) |
| June 2020 | - | -$18.90 M(-18.8%) | -$70.36 M(+17.0%) |
| Mar 2020 | - | -$23.27 M(+32.5%) | -$60.15 M(+29.7%) |
| Dec 2019 | -$46.38 M | -$17.57 M(+65.3%) | -$46.38 M(+20.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$10.63 M(+22.4%) | -$38.60 M(+13.9%) |
| June 2019 | - | -$8.68 M(-8.6%) | -$33.89 M(+3.1%) |
| Mar 2019 | - | -$9.50 M(-3.0%) | -$32.87 M(+9.4%) |
| Dec 2018 | -$30.05 M(+13.5%) | -$9.79 M(+65.7%) | -$30.05 M(+13.2%) |
| Sept 2018 | - | -$5.91 M(-22.9%) | -$26.55 M(-2.0%) |
| June 2018 | - | -$7.67 M(+14.8%) | -$27.09 M(+2.2%) |
| Mar 2018 | - | -$6.68 M(+6.2%) | -$26.52 M(+0.2%) |
| Dec 2017 | -$26.47 M(+24.4%) | -$6.29 M(-2.4%) | -$26.47 M(-3.4%) |
| Sept 2017 | - | -$6.45 M(-9.1%) | -$27.40 M(+6.4%) |
| June 2017 | - | -$7.10 M(+6.9%) | -$25.75 M(+7.4%) |
| Mar 2017 | - | -$6.64 M(-8.0%) | -$23.97 M(+12.6%) |
| Dec 2016 | -$21.28 M(+186.1%) | -$7.22 M(+50.3%) | -$21.28 M(+30.4%) |
| Sept 2016 | - | -$4.80 M(-9.6%) | -$16.32 M(+21.4%) |
| June 2016 | - | -$5.31 M(+34.6%) | -$13.44 M(+31.4%) |
| Mar 2016 | - | -$3.95 M(+75.4%) | -$10.23 M(+37.5%) |
| Dec 2015 | -$7.44 M(+61.8%) | -$2.25 M(+17.1%) | -$7.44 M(+43.4%) |
| Sept 2015 | - | -$1.92 M(-8.7%) | -$5.19 M(+58.9%) |
| June 2015 | - | -$2.11 M(+81.8%) | -$3.27 M(+181.8%) |
| Mar 2015 | - | -$1.16 M | -$1.16 M |
| Dec 2014 | -$4.60 M(+181.8%) | - | - |
| Dec 2013 | -$1.63 M | - | - |
FAQ
- What is Axsome Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Axsome Therapeutics?
- What is Axsome Therapeutics annual CFO year-on-year change?
- What is Axsome Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Axsome Therapeutics?
- What is Axsome Therapeutics quarterly CFO year-on-year change?
- What is Axsome Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Axsome Therapeutics?
- What is Axsome Therapeutics TTM CFO year-on-year change?
What is Axsome Therapeutics annual cash flow from operations?
The current annual CFO of AXSM is -$145.08 M
What is the all time high annual CFO for Axsome Therapeutics?
Axsome Therapeutics all-time high annual cash flow from operations is -$1.63 M
What is Axsome Therapeutics annual CFO year-on-year change?
Over the past year, AXSM annual cash flow from operations has changed by -$28.57 M (-24.52%)
What is Axsome Therapeutics quarterly cash flow from operations?
The current quarterly CFO of AXSM is -$18.63 M
What is the all time high quarterly CFO for Axsome Therapeutics?
Axsome Therapeutics all-time high quarterly cash flow from operations is -$1.16 M
What is Axsome Therapeutics quarterly CFO year-on-year change?
Over the past year, AXSM quarterly cash flow from operations has changed by +$11.73 M (+38.64%)
What is Axsome Therapeutics TTM cash flow from operations?
The current TTM CFO of AXSM is -$132.57 M
What is the all time high TTM CFO for Axsome Therapeutics?
Axsome Therapeutics all-time high TTM cash flow from operations is -$1.16 M
What is Axsome Therapeutics TTM CFO year-on-year change?
Over the past year, AXSM TTM cash flow from operations has changed by +$12.51 M (+8.62%)